MX2021008819A - Analogos de cisteamina resistentes a la ado y sus usos. - Google Patents

Analogos de cisteamina resistentes a la ado y sus usos.

Info

Publication number
MX2021008819A
MX2021008819A MX2021008819A MX2021008819A MX2021008819A MX 2021008819 A MX2021008819 A MX 2021008819A MX 2021008819 A MX2021008819 A MX 2021008819A MX 2021008819 A MX2021008819 A MX 2021008819A MX 2021008819 A MX2021008819 A MX 2021008819A
Authority
MX
Mexico
Prior art keywords
ado
diseases
resistant
analogs
cysteamine
Prior art date
Application number
MX2021008819A
Other languages
English (en)
Inventor
Benoit Gourdet
Todd C Zankel
John Unitt
Timothy Phillips
Loma Duffy
Original Assignee
Horizon Orphan Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Orphan Llc filed Critical Horizon Orphan Llc
Publication of MX2021008819A publication Critical patent/MX2021008819A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/26—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/30—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención está dirigida a análogos de cisteamina resistentes a la ADO para usarse en métodos para tratar enfermedades para las cuales las cisteamida está indicada, en particular cistinosis, enfermedad de hígado graso, fibrosis, enfermedades trombóticas, trastornos relacionados con MECP-2, enfermedades hereditarias en las mitocondrias, enfermedades o trastornos neurológicos, inflamación y cáncer.
MX2021008819A 2015-07-02 2018-01-08 Analogos de cisteamina resistentes a la ado y sus usos. MX2021008819A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187939P 2015-07-02 2015-07-02
US201562387337P 2015-12-23 2015-12-23

Publications (1)

Publication Number Publication Date
MX2021008819A true MX2021008819A (es) 2021-08-24

Family

ID=56511899

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000202A MX2018000202A (es) 2015-07-02 2016-07-01 Analogos de cisteamina resistentes a la ado y sus usos.
MX2021008819A MX2021008819A (es) 2015-07-02 2018-01-08 Analogos de cisteamina resistentes a la ado y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000202A MX2018000202A (es) 2015-07-02 2016-07-01 Analogos de cisteamina resistentes a la ado y sus usos.

Country Status (14)

Country Link
US (2) US10906904B2 (es)
EP (1) EP3316877B1 (es)
JP (2) JP2018525350A (es)
KR (1) KR20180034466A (es)
CN (1) CN108289867A (es)
AU (2) AU2016288230A1 (es)
BR (1) BR112017028448A2 (es)
CA (1) CA2991099A1 (es)
ES (1) ES2770113T3 (es)
IL (1) IL256553B (es)
MX (2) MX2018000202A (es)
RU (2) RU2766579C2 (es)
TW (2) TW202247838A (es)
WO (1) WO2017004485A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2766579C2 (ru) 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
EP3615013A1 (en) * 2017-04-24 2020-03-04 Mercaptor Discoveries, Inc. Use of thiol compounds to treat neurological disease
KR102490204B1 (ko) 2018-03-01 2023-01-19 오브비아 파마슈티컬즈 리미티드 신규 아미노티올로 허혈-재관류에 의해 유발된 세포사멸을 감소하는 방법
WO2019210035A1 (en) * 2018-04-25 2019-10-31 Horizon Orphan Llc Methods of treating excitotoxicity disorders

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2834785A (en) 1954-11-16 1958-05-13 Lakeside Lab Inc N-substituted-3-thiol piperidines and thioesters thereof
GB780027A (en) 1955-01-20 1957-07-31 Schering Corp 3-piperidyl ethers and thioethers
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
FR2549064B1 (fr) 1983-07-13 1985-10-25 Rhone Poulenc Sante Nouveaux derives de synergistines utiles pour la preparation de nouveaux medicaments antimicrobiens et leur preparation
PH23995A (en) 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
DE3586746D1 (de) 1984-04-03 1992-11-19 Takeda Chemical Industries Ltd Lipidderivate, ihre produktion und verwendung.
PH22302A (en) 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5071846A (en) 1987-07-01 1991-12-10 Janssen Pharmaceutica N.V. Anti-hystaminic [(bicyclic heterocyclyl) methyl and --hetero] substituted hexahydro-1H-azepines and pyrrolidines
US5151424A (en) 1987-07-01 1992-09-29 Janssen Pharmaceutica N.V. Pharmacologically active (Bicyclic heterocyclyl)methyl and -hetero) substituted hexahydro-1H-azepines and pyrrolidines
US4988689A (en) 1987-07-01 1991-01-29 Janssen Pharmaceutica N.V. ((Pharmacologically active bicyclic heterocyclic)methyl and -heteroatom) substituted hexahydro-1H-azepines and pyrrolidines
GB2206879A (en) 1987-07-07 1989-01-18 May & Baker Ltd Novel pristinamycin IIB derivatives, their preparation and pharmaceutical compositions containing them
DE3808678A1 (de) 1988-03-11 1989-09-21 Schering Ag Anellierte imino-azole, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider wirkung
EP0339406A1 (en) 1988-04-19 1989-11-02 Hokuriku Pharmaceutical Co.,Ltd Quinoline-3-carboxylic acid derivatives, process for preparing the same, and composition exhibiting excellent antibacterial effect containing the same
FR2635524B1 (fr) 1988-08-19 1992-04-24 Adir Nouveaux derives de benzopyrrolidinone, leur procede de preparation et les compositions pharmaceutiques les renfermant
US5272150A (en) 1989-04-07 1993-12-21 Janssen Pharmaceutica N.V. Hydroxyalkylfuranyl derivatives
CA2015949A1 (en) 1989-05-22 1990-11-22 Yasuo Ito Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
JPH03118319A (ja) * 1989-09-30 1991-05-20 Green Cross Corp:The 抗炎症剤、胃液分泌抑制剤または活性酸素産生抑制剤
FR2655649B1 (fr) 1989-12-12 1994-07-08 Adir Nouveaux derives de la piperidine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5217980A (en) 1990-07-19 1993-06-08 Janssen Pharmaceutica N.V. Oxazolyl and piperidinyl substituted benimidazolyl compounds
TW198027B (es) 1990-08-26 1993-01-11 Sankyo Co
KR950005301B1 (ko) 1990-09-04 1995-05-23 주식회사대웅제약 신규한 퀴놀론 카르복실산 유도체
JPH04334357A (ja) 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
MX9205549A (es) * 1991-09-30 1993-05-01 Jess G Thoene Metodo para el tratamiento de vih.
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
ATE181735T1 (de) 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
FR2705346B1 (fr) 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
US5783703A (en) 1993-07-01 1998-07-21 Lederle (Japan), Ltd. Sulfur-containing compounds method for their use and prodction
WO1996004274A1 (en) 1994-08-02 1996-02-15 Merck Sharp & Dohme Limited Azetidine, pyrrolidine and piperidine derivatives
US5929247A (en) 1994-10-24 1999-07-27 Eli Lilly And Company Heterocyclic compounds and their preparation and use
ATE201410T1 (de) 1994-12-12 2001-06-15 Wyeth Lederle Japan Ltd Verfahren zur herstellung von 1-(4,5-dihydro)2- thiazolyl-3-azetidinthiolderivaten
JP3724854B2 (ja) 1995-09-11 2005-12-07 ワイス株式会社 １−アザビシクロ［１．１．０］ブタンの製造法
GB9523243D0 (en) 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
JP3209679B2 (ja) 1996-04-05 2001-09-17 日本ワイスレダリー株式会社 ジスルフィド化合物およびその製造法
GB9610979D0 (en) 1996-05-24 1996-07-31 Merck Sharp & Dohme Therapeutic agents
JPH1143792A (ja) 1997-07-23 1999-02-16 Asahi Kagaku Kogyo Co Ltd 酸洗促進剤、酸洗促進剤を含んだ酸洗液組成物およびこれを用いる酸洗方法
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
WO1999036403A1 (en) 1998-01-13 1999-07-22 The Trustees Of The University Of Pennsylvania Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same
CA2333554A1 (en) 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
AU5450199A (en) 1998-09-10 2000-04-03 Wyeth Lederle Japan, Ltd. Carbapenem compounds
AU6508899A (en) * 1998-10-13 2000-05-01 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
AU763000B2 (en) * 1998-10-30 2003-07-10 Nicox S.A. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
BR9806353A (pt) * 1998-11-10 2000-06-20 Univ Minas Gerais Processo para a preparação e aplicação farmacológica de novos beta-aminotióis e respectivos sais
JP2001131067A (ja) * 1999-08-26 2001-05-15 Sankyo Co Ltd 血小板凝集抑制剤又は動脈硬化進展抑制剤
US6455573B1 (en) 2000-01-07 2002-09-24 Simon Fraser University Glycosidase inhibitors and methods of synthesizing same
US6369243B1 (en) 2000-01-18 2002-04-09 The Regents Of The Univerisity Of California Chemical transformation of substrates using nonmetallic, organic catalyst compositions
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001278479B2 (en) 2000-07-19 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as metalloprotease inhibitors
US20040209959A1 (en) 2001-07-16 2004-10-21 Edward Hogestatt Congeners of acetaminophen and related compounds as substrates for fatty acid conjugation and their use in treatment of pain, fever and inflammation
JP2003183281A (ja) 2001-12-21 2003-07-03 Wyeth Lederle Japan Ltd カルバペネム化合物
JP2003183280A (ja) 2001-12-21 2003-07-03 Wyeth Lederle Japan Ltd カルバペネム化合物
EP1467986A1 (en) 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
US6743864B2 (en) 2002-03-12 2004-06-01 Basell Poliolefine Italia S.P.A. Polyolefin compositions having high tenacity
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
SE0300812D0 (sv) 2003-03-24 2003-03-24 Karolinska Innovations Ab Use of chemical compounds for preparing pharmaceutical compositions, and method of testing substances for medical effect
ES2388547T3 (es) 2003-04-18 2012-10-16 Eli Lilly And Company Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas de 5-HT 1F
WO2005014524A2 (en) * 2003-08-07 2005-02-17 Wisconsin Alumni Research Foundation Amino thiol compounds and compositions for use in conjunction with cancer therapy
ES2335284T3 (es) 2003-09-03 2010-03-24 Glaxo Group Limited Nuevo procedimiento para preparar derivados de pleuromutilina.
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
WO2005039548A2 (en) * 2003-10-15 2005-05-06 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
EP1541143A1 (en) 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Dpp-iv inhibitors
WO2005063226A1 (en) 2003-12-19 2005-07-14 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
CN101822658A (zh) 2004-05-03 2010-09-08 奥加生物药业(I.P.3)有限公司 半胱胺用于治疗高胆固醇血症和糖尿病并发症
JP2006001841A (ja) 2004-06-15 2006-01-05 Sumitomo Chemical Co Ltd 含窒素へテロ環化合物の製造方法
PL1637141T3 (pl) 2004-09-21 2012-04-30 Trobio Ab Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
SG158860A1 (en) 2005-01-13 2010-02-26 Wyeth Corp Processes for the preparation of aminoethoxybenzyl alcohols
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN101196230A (zh) 2006-01-06 2008-06-11 赵文利 机械动力多司调制技术
EA201600089A1 (ru) 2006-01-27 2017-01-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
TWI389917B (zh) 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
WO2008128919A2 (en) * 2007-04-19 2008-10-30 Ucb Pharma S.A. Histamine h3 receptor ligands comprising a cyclobutoxy group
US20090163705A1 (en) 2007-05-21 2009-06-25 Alnylam Pharmaceuticals, Inc. Cationic lipids
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
DE102008032561A1 (de) 2007-07-16 2009-01-22 Basf Se Verfahren und Mischung zur Reinigung von Alkinen
US8026285B2 (en) 2007-09-04 2011-09-27 Bezwada Biomedical, Llc Control release of biologically active compounds from multi-armed oligomers
CA2706768C (en) 2007-11-30 2016-06-28 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
WO2009121812A1 (en) 2008-03-31 2009-10-08 Evotec Neurosciences Gmbh Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010015815A2 (en) 2008-08-05 2010-02-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010026113A1 (en) 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
WO2010041964A1 (en) 2008-10-09 2010-04-15 Victoria Link Limited Methods for the preparation of alkenylamines, cyclic carbamates or dithiocarbamates, and aminoalcohols or aminothiols
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
WO2010060952A1 (en) 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CN102471235A (zh) 2009-07-11 2012-05-23 拜耳医药股份有限公司 利用环烷基的放射性标记方法
DK2501693T3 (en) 2009-11-18 2014-12-08 Fab Pharma Sas Aza-heterocyclic acrylamides and their use as bactericides
TWI485153B (zh) 2010-01-13 2015-05-21 Sanofi Aventis ２，５，７－經取代唑并嘧啶衍生物
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
MX2013004577A (es) * 2010-10-25 2014-06-23 Univ Aix Marseille Ii Tratamiento de trastornos asociados a mecp2.
US20120309785A1 (en) * 2010-12-03 2012-12-06 Bill Piu Chan Use of Cysteamine in Treating Parkinson's Disease
CA2732440C (en) 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
WO2013024376A1 (en) 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
WO2013062544A1 (en) * 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
SG10201800159QA (en) * 2011-11-22 2018-02-27 Univ California Cysteamine and/or cystamine for treating ischemic injury
EP2601940A1 (en) * 2011-12-05 2013-06-12 Lacer, S.A. (4-mercapto-piperidin-4-yl)-aminoacetic acid derivatives, pharmaceutical compositions and uses thereof
TW201605434A (zh) * 2013-11-06 2016-02-16 雷普特製藥有限公司 使用半胱胺及其衍生物治療粒腺體疾病
WO2015150472A2 (en) 2014-04-01 2015-10-08 Université Libre de Bruxelles New strategies for treating melanoma
CA2947041A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
RU2766579C2 (ru) 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение

Also Published As

Publication number Publication date
CN108289867A (zh) 2018-07-17
US20170002004A1 (en) 2017-01-05
IL256553A (en) 2018-02-28
TWI759267B (zh) 2022-04-01
WO2017004485A1 (en) 2017-01-05
TW201713324A (zh) 2017-04-16
RU2766579C2 (ru) 2022-03-15
JP2018525350A (ja) 2018-09-06
AU2016288230A1 (en) 2018-01-25
US11505550B2 (en) 2022-11-22
BR112017028448A2 (pt) 2018-08-28
EP3316877B1 (en) 2019-10-30
TW202247838A (zh) 2022-12-16
AU2021200321A1 (en) 2021-03-18
CA2991099A1 (en) 2017-01-05
RU2022103033A (ru) 2022-04-01
US20220024920A1 (en) 2022-01-27
IL256553B (en) 2021-03-25
RU2018103901A3 (es) 2020-05-25
EP3316877A1 (en) 2018-05-09
US10906904B2 (en) 2021-02-02
KR20180034466A (ko) 2018-04-04
ES2770113T3 (es) 2020-06-30
RU2018103901A (ru) 2019-08-05
JP2021152087A (ja) 2021-09-30
MX2018000202A (es) 2018-06-27

Similar Documents

Publication Publication Date Title
IL298689B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
EP3349783C0 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH THE TREATMENT OF DISEASES
IL280710A (en) Methods and compositions for the treatment of mitochondrial diseases or and troplasmic disorders
EP3359662A4 (en) COMPOSITIONS AND METHODS OF TREATING HUNTINGTON DISEASE AND RELATED DISEASES
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
EP3526319A4 (en) METHOD AND COMPOSITIONS AND FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL VENTILATION SYSTEM
IL260352B (en) Methods and preparations for the treatment of neurological disease
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
IL262348A (en) Preparations for the treatment of excessive radiation disorders
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
MX2021008819A (es) Analogos de cisteamina resistentes a la ado y sus usos.
EP3507371A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM
EP3538119A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
IL264070A (en) Methods and preparations for the treatment of disorders and diseases involving rdh12
MX2017014782A (es) Metodo para el tratamiento de enfermedad neurologica.
MX2022015456A (es) Composiciones de maca y metodos de uso.
EP3215222A4 (en) Methods of treating huntington&#39;s disease using cysteamine compositions
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
EP3362085C0 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH MUCIN
HK1258884A1 (zh) 用於治療竇疾病和病症的組合物和方法
ZA201801945B (en) Compositions and methods for the treatment of parkinson&#39;s disease